---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-23-000008"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:40:54.434296+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tandem Diabetes completes acquisition of AMF Medical for CHF 70.4M upfront plus earnouts

## Summary
- Total upfront consideration: CHF 8.0M strategic investment (Q3 2022) plus CHF 62.4M cash at closing.
- Acquisition closed on January 19, 2023; additional contingent earnout payments may follow.
- Target: AMF Medical SA, a Swiss diabetes technology company; adds to Tandem's product portfolio.
- Transaction previously disclosed in December 2022; Purchase Agreement filed with 8-K.

## SEC filing metadata
- accession: 0001438133-23-000008
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000008/0001438133-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000008/tndm-20230119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-23-000008
- JSON: https://secwatch.observer/filing/0001438133-23-000008.json
- Plain text: https://secwatch.observer/filing/0001438133-23-000008.txt

## Key facts
- M&A Transactions
  TANDEM DIABETES CARE INC completed an acquisition involving AMF Medical SA for a previous strategic investment of Swiss Francs ("CHF") 8.0 million paid in the third quarter of 2022, a cash payment of CHF 62.4 million paid at the closing of (closed 2023-01-19).
  - Action: acquisition
  - Counterparty: AMF Medical SA
  - Consideration: a previous strategic investment of Swiss Francs ("CHF") 8.0 million paid in the third quarter of 2022, a cash payment of CHF 62.4 million paid at the closing of
  - Closing: 2023-01-19
  source text: e Company entered into a Share Purchase Agreement, dated as of December 10, 2022 (the “Purchase Agreement”), by and among the Company, the Sellers listed on Annex B of the Purchase Agreement (collectively, the “Sellers” and each, individually, a “Seller”) and AMF Medical SA, a corporation organized and existing under the laws of Switzerland (“AMF Medical”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000008/0001438133-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.